openPR Logo
Press release

Diseases & Conditions Analysis - Peanut Allergy - Pipeline Review, H1 2017

05-15-2017 01:42 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Peanut Allergy

Diseases & Conditions Analysis - Peanut Allergy - Pipeline

"Peanut Allergy - Pipeline Review, H1 2017" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect.

Description-

-- Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peanut Allergy - Pipeline Review, H1 2017, provides an overview of the Peanut Allergy (Immunology) pipeline landscape.

Peanut allergy is common, especially in children. An allergic response to peanuts usually occurs within minutes after exposure, and symptoms range from mild to severe. Peanut allergy signs and symptoms can include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, digestive problems, such as diarrhea, stomach cramps, nausea or vomiting, tightening of the throat, shortness of breath or wheezing and runny nose.

Get Sample Report With TOC @ http://bit.ly/2pGjyLz

-- Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peanut Allergy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Peanut Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peanut Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Peanut Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4, 8 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Peanut Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

** Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Peanut Allergy (Immunology).
- The pipeline guide reviews pipeline therapeutics for Peanut Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Peanut Allergy (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Peanut Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Peanut Allergy (Immunology)

** Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Peanut Allergy (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Peanut Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Researchmoz Global Pvt. Ltd.
90 State Street,
Albany, NY 12207,
United States,
Tel: 866-997-4948 (Us-Canada Toll Free),
Tel: +1-518-621-2074

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Diseases & Conditions Analysis - Peanut Allergy - Pipeline Review, H1 2017 here

News-ID: 535139 • Views:

More Releases for Immunology

Alta DiagnoTech Releases ELISA Kits for IVD Immunology Testing
Alta DiagnoTech announced the release of its highly sensitive and reliable ELISA kits specifically designed for IVD in immunology testing. New York, USA - January 31, 2025 - As a top supplier of clinical diagnostic products, Alta DiagnoTech introduced ELISA (Enzyme-Linked Immunosorbent Assay) kits designed for in vitro diagnostics (IVD) applications in immunology testing due to their high sensitivity and reliability. Through this initiative Alta DiagnoTech intends to boost diagnostic performance
Empowering Immunology: Creative Biolabs' Streamlined Pathway for IgE Antibodies
The success of their efforts to utilize the power of antibody engineering technologies has now permitted Creative Biolabs to include the anti-IgE antibody among its offerings. New York, USA - November 13, 2024 - The current situation leads us to believe that the value of IgE antibodies [https://non-igg-ab.creative-biolabs.com/category-ige-344.htm] in immunology research has grown significantly. "What makes IgE antibodies fascinating is the fact that they not only identify the pathological mechanisms of
Immunology Drugs Market Research Report 2023 | InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Global Immunology Drugs Market By Drug Class (Monoclonal antibodies, Fusion Proteins, Immunosuppressants, Polyclonal antibodies, and Other Drug classes), Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), Disease Indications (Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, and Other disease Indication))- Trends, Industry Competition Analysis, Revenue and Forecast To 2030." According to the
Immunology Market - Shaping the Immune Landscape: Transforming Healthcare with C …
Newark, New Castle, USA - new report, titled Immunology Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Immunology market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Immunology market. The report offers an overview of the market, which briefly describes the
Immunology Biosimilars Market Boosting the Healthcare Industry Worldwide
A biosimilar medicine possesses similar pharmacokinetic and mode of action as an original biological medicine that has already been approved for therapeutic use. Biosimilars are made from a living organism such as bacteria and yeast or can also be derived from small molecules such as human insulin, erythropoietin, and monoclonal antibodies via recombinant DNA and gene expression technologies. Biosimilars are developed only when original biological medicines are commercially expired and
16th International Conference on European Immunology
Meet leading Immunology Experts, Immunity Health Speakers, Immunologist Researchers, Neuro Immunology Scientists from Amsterdam, Netherlands, New York, Valencia, Frankfurt, London, Dubai, Chicago, France, China, all over the world at European Immunology Conference 2022| May 02-03, 2022 Zurich, Switzerland 35 Ruddlesway, Windsor, Berkshire, SL4 5SF Meet leading Immunology Experts, Immunity Health Speakers, Immunologist Researchers, Neuro Immunology Scientists from Amsterdam, Netherlands, New York, Valencia, Frankfurt, London, Dubai, Chicago, France,